PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical- stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be availabl ...